A lawsuit has been filed in the USA against Copley Pharmaceuticals, a subsidiary of Hoechst, claiming that contamination of its asthma medication albuterol with the bacterium Pseudomonas flourescens caused the death of 40 people, including eight children.
The suit is for $100 million in punitive damages, plus actual damages. The claim is the biggest outside the Federal Court where a class action suit based on more than 36 suits is pending.
Albuterol was withdrawn from sale in January last year after contamination of the product with the bacterium, a generally benign strain found in tap water, was discovered.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze